# Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Source: https://onco.cc/trials/nct05827081/  
OnCo record `nct05827081` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ribociclib and Exemestane in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer is a phase 3 interventional study registered as NCT05827081 by Novartis Pharmaceuticals, with 1400 participants planned, started 2024-02-28 and due to reach its primary completion in 2029-09-07. Interventions recorded: Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide and Exemestane.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05827081
- Phase: 3
- Setting: A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 1400

## Sources

- ClinicalTrials.gov NCT05827081: https://clinicaltrials.gov/study/NCT05827081

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Exemestane](https://onco.cc/drugs/exemestane/), [Ribociclib](https://onco.cc/drugs/ribociclib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct05827081.json